Compare · PFE vs PLYX
PFE vs PLYX
Side-by-side comparison of Pfizer Inc. (PFE) and Polaryx Therapeutics Inc. (PLYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and PLYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $153.59B, about 668.9x PLYX ($229.6M).
- Over the past year, PFE is up 17.1% and PLYX is down 86.0% - PFE leads by 103.1 points.
- PFE has been more active in the news (10 items in the past 4 weeks vs 3 for PLYX).
- PFE has more recent analyst coverage (25 ratings vs 1 for PLYX).
- Company
- Pfizer Inc.
- Polaryx Therapeutics Inc.
- Price
- $26.98+1.20%
- $4.86-7.69%
- Market cap
- $153.59B
- $229.6M
- 1M return
- -1.21%
- -23.52%
- 1Y return
- +17.13%
- -85.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 1
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest PLYX
- Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
- Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
- Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
- Maxim Group initiated coverage on Polaryx Therapeutics with a new price target
- Chief Financial Officer Landis G. Michael bought $7,991 worth of shares (2,867 units at $2.79), increasing direct ownership by 1% to 228,225 units (SEC Form 4)
- Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial